Dogs of the Dow Are Rising While the S&P Falls — Is the Value Rotation Finally Here?
On Tuesday, May 19, the S&P 500 fell 0.42% to 7,372 while the Dow Jones Industrial Average held relatively steady, buoyed by a striking divergence: the Dogs of the Dow — the ten highest-yielding dividend stocks in the Dow 30 — are outperforming the broader market today. Dominion Energy surged on the NextEra acquisition, Home Depot reported earnings that beat estimates, and defensive names like Verizon, Chevron, and Coca-Cola are attracting buyers as AI-infrastructure stocks pull back for a second straight session. The question the market is now asking: is this the beginning of a genuine rotation from growth to value, and does it have enough momentum to push the Dow past 50,000 and hold it there?
The Dow vs. the S&P 500: They Are Not the Same Index
Most people treat the Dow and the S&P 500 as interchangeable gauges of the U.S. stock market. They are not. The Dow Jones Industrial Average is a price-weighted index of just 30 large-cap American companies — meaning a stock with a higher share price has more influence over the index than one with a lower price, regardless of market capitalization. Goldman Sachs, trading above $600, has an outsized impact. Apple, despite being one of the world’s most valuable companies, has a relatively modest influence because of its lower per-share price post-split. The Dow was created in 1896 and its 30 components skew toward established, dividend-paying industrial and financial companies.
The S&P 500 is a market-cap-weighted index of 500 companies. Apple, NVIDIA, Microsoft, Amazon, and Meta collectively drive a disproportionate share of its daily performance — tech and AI-adjacent stocks account for roughly 30% of the S&P 500’s total weight. When Seagate dropped nearly 7% on Monday after its CEO expressed concerns about factory buildout timing, Micron followed it down around 6%, and the S&P and Nasdaq both slid. The Dow, which has neither stock, rose 160 points or 0.32% to close at 49,686. That structural difference is precisely why today’s divergence is happening.
What Are the Dogs of the Dow?
The Dogs of the Dow is one of the oldest and simplest investing strategies on Wall Street, popularized by investor Michael O’Higgins in the early 1990s. Each year, identify the 10 stocks in the Dow 30 with the highest dividend yields, invest equally in all 10, hold for the full year, then rebalance and repeat. The logic is contrarian: a high dividend yield may indicate a blue-chip stock has become temporarily cheap after share-price weakness. The strategy had its strongest performance since 2019 in 2025, gaining 17% — ahead of the Dow’s 13.7% return. The average yield at the start of 2026 was 3.3%, more than twice the S&P 500 average.
The 2026 Dogs of the Dow are: Verizon (VZ), Chevron (CVX), UnitedHealth (UNH), Merck (MRK), Amgen (AMGN), Procter & Gamble (PG), Coca-Cola (KO), Home Depot (HD), Nike (NKE), and Johnson & Johnson (JNJ).
Stock-by-Stock Breakdown
Verizon (VZ) — Yield: 6.8% — ~$46.85
The highest-yielding Dog. Q1 2026 EPS of $1.28 beat estimates by 5.79%, with record adjusted EBITDA of $13.4B up 6.7% year-over-year and its highest EPS growth since 2021 — plus its first postpaid phone net adds in 13 years. Free cash flow hit $3.8B, up 4% YoY, with full-year FCF guidance of $21.5B+. Recent catalysts include AT&T, T-Mobile, and Verizon forming a joint venture to end wireless dead zones via satellite — a direct challenge to Starlink. Price target raised to $52. Trades at just 8.5x 2026 earnings — one of the cheapest valuations in the Dow.
Chevron (CVX) — Yield: 4.5% — ~$158
Up more than 20% in 2026, driven by Brent crude above $109 per barrel amid the Iran conflict. Goldman Sachs raised its price target to $216, keeping a Buy rating. Chevron is a Dividend Aristocrat that raised its dividend 4% entering 2026 and is a top Berkshire Hathaway holding. Key risk: any Iran peace deal progress could deflate oil prices sharply — shares tumbled recently on signs the Trump administration is nearing a deal.
Home Depot (HD) — Yield: ~3% — ~$299
HD reported Q1 fiscal 2026 earnings this morning. Adjusted EPS of $3.43 beat the $3.41 estimate. Revenue of $41.77B beat forecasts and grew roughly 5% year-over-year. Full-year 2026 guidance reaffirmed: total sales growth of 2.5%–4.5%, adjusted EPS growth flat to 4%. The miss: same-store sales grew just 0.6% vs. 0.9% expected. CFO Richard McPhail cautioned that homeowners are deferring bigger-ticket projects. HD is down 21% over the past 12 months, making it a deep value play with a Strong Buy consensus and average price target of $403.58 — implying 35% upside.
Merck (MRK) — Yield: ~3.5% — ~$88
Under pressure from long-term Keytruda patent cliff concerns — its blockbuster cancer drug faces biosimilar competition later this decade — but near-term earnings remain solid and the dividend is well-covered. One of three healthcare Dogs (alongside Amgen and JNJ) that analysts flagged as attractive heading into 2026 as regulatory concerns from Washington eased. Healthcare represents 40% of the Dogs basket weighting this year.
Amgen (AMGN) — Yield: ~3.2% — ~$285
One of the stronger performers in the Dogs basket YTD, lifted by its obesity drug pipeline and a rebound in healthcare sentiment. Amgen’s MariTide weight-loss drug is in late-stage trials and represents a potential multi-billion-dollar revenue stream. Amgen was up between 28% and 44% in 2025 and its dividend has grown consistently. A genuine dual catalyst play: value income plus pipeline optionality.
Johnson & Johnson (JNJ) — Yield: ~3.1% — ~$162
Over 60 consecutive years of dividend growth. The spinoff of Kenvue left JNJ as a purer pharmaceutical and MedTech play. The talc litigation overhang that plagued the stock for years has largely been resolved. JNJ is a classic safety trade in risk-off environments — and with the S&P sliding on AI chip concerns, defensive capital is flowing exactly here.
Coca-Cola (KO) — Yield: ~3.0% — ~$71
Warren Buffett’s most iconic holding. Over 60 consecutive years of annual dividend increases. KO’s global pricing power — products sold in virtually every country — provides a natural inflation hedge. With the 10-year Treasury yield elevated and the Fed on hold, KO’s 3% yield with near-zero business model risk is attracting conservative capital rotating out of high-multiple tech.
Procter & Gamble (PG) — Yield: ~2.6% — ~$165
The one Dog that finished 2025 in the red, making it the most contrarian pick in the 2026 basket. PG makes Tide, Gillette, and Pampers — products whose demand is largely insensitive to economic cycles. Input cost inflation squeezed margins but pricing power is allowing gradual recovery. A classic defensive name that tends to outperform when growth stocks sell off.
Nike (NKE) — Yield: ~2.5% — ~$56
The most troubled Dog. NKE joined the list because its stock has been crushed as the company lost market share to On Running, Hoka, and New Balance, and struggled with its DTC pivot and inventory issues. New CEO Elliott Hill is executing a turnaround, rebuilding wholesale relationships and refocusing on sport performance. Wall Street’s 12-month consensus implies 21% upside, but NKE is the Dog most at risk of being a value trap. Tariff exposure on Asian manufacturing is a near-term headwind.
UnitedHealth (UNH) — Yield: ~1.8% — ~$290
The most dramatic story in the basket. UNH collapsed from above $600 to below $300 following the murder of CEO Brian Thompson in December 2024, which triggered a wave of public backlash against health insurers and accelerating government scrutiny. The company guided for at least $17.75 in adjusted EPS for 2026 but guided for revenue roughly $17 billion light of consensus. At current levels it trades at one of its cheapest valuations in a decade — either the deepest value play in the basket or a value trap, depending on how Washington’s healthcare policy debate evolves.
Is the Value Rotation Real?
Today’s divergence raises a question strategists have debated all year: is the AI trade concentration in the S&P creating a structural case for rotating into value and dividend stocks? Tech stocks have contributed 85% of the S&P 500’s total return YTD — a level of concentration that historically precedes mean reversion. The 10-year Treasury yield hitting its highest level in a year makes dividend-paying stocks more attractive on a relative basis. Several Dogs — Verizon, Chevron, Coca-Cola, JNJ — offer free cash flow, manageable debt, stable earnings, and reliable dividends that check every box a conservative allocator needs.
The counterargument is equally real: if NVIDIA blows out earnings Wednesday and guides above $85 billion for Q2, the AI trade roars back, growth money stays in tech, and the Dogs return to being afterthoughts. The strategy works best as a diversification tool against AI concentration risk, not as a wholesale replacement for growth exposure.
Will the Dow Hold 50,000?
The Dow crossed 50,000 for the first time ever on May 14, rising more than 350 points as NVIDIA surged 4%+ on H200 chip sales approval for China and Goldman Sachs and Caterpillar did their usual heavy lifting. Today the Dow sits at 49,686 — just 314 points below that milestone. Whether it holds above 50,000 sustainably comes down to Wednesday’s NVIDIA print. A beat-and-raise gives the Dow the tech lift from Goldman, Microsoft, and NVIDIA — added to the index in November 2024 — needed to push through 50,000 convincingly, with the prior all-time high around 50,500 as the next bull target. A NVDA disappointment keeps the rotation into Dow defensives alive but makes the path to a sustained 50,000 breakout slower and harder.
The Dogs of the Dow outperforming on a down-S&P day is a signal that investors are beginning to hedge their AI concentration risk with cash-generating, dividend-paying blue-chip businesses that have survived every recession, every market cycle, and every technological disruption for the past century. Whether that hedge becomes a full rotation depends on what Jensen Huang says Wednesday evening.
This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
About the Author
